Von Roemeling et al reported that SCD1 might be a novel molecular therapeutic target for clear cell renal cell carcinoma, for which increased SCD1 expression was observed in ccRCC and it was essentially associated with ccRCC viability[19]. This evidence concerns the gene SCD and nonpapillary renal cell carcinoma.